Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 3/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354467 | 1.00 | USP2 (0.50) | USP2GAAALOX15RAD51NPSR1 | |
| Hydrochloric Acid SCHEMBL3824712 | 0.98 | USP2 (0.48) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL28482610 | 0.83 | TYR (0.50) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL21090062 | 0.79 | HDAC6 (0.43) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL3831376 | 0.76 | IMPDH2 (0.52) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL30088200 | 0.76 | IMPDH2 (0.52) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL13778764 | 0.76 | HDAC6 (0.48) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL8664673 | 0.75 | PDPK1 (0.47) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL587359 | 0.75 | AHR (0.50) | USP2GAAALOX15RAD51NPSR1 | |
| SCHEMBL8296659 | 0.75 | CYP2A6 (0.47) | USP2GAAALOX15RAD51NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784404-A4 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORP (KR) | 2009-09-09 | — | — | EP | claimed |
| JP-2008511621-A | — | — | 2008-04-17 | — | — | JP | claimed |
| EP-1784404-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | Yuhan Corporation (KR) | 2007-05-16 | — | — | EP | claimed |
| WO-2006025716-A1 | PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 2006-03-09 | — | — | WO | claimed |
| EP-4635954-A1 | INDUCER FOR INDUCING MESENCHYMAL-EPITHELIAL TRANSITION AND REPROGRAMMING | Iregene Therapeutics Co., Ltd (CN) | 2025-10-22 | — | — | EP | disclosed |
| EP-4611743-A1 | TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | Merck Sharp & Dohme LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024124464-A1 | INDUCER FOR INDUCING MESENCHYMAL-EPITHELIAL TRANSITION AND REPROGRAMMING | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024124464-A1 | INDUCER FOR INDUCING MESENCHYMAL-EPITHELIAL TRANSITION AND REPROGRAMMING | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024124463-A1 | PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024124463-A1 | PYRROLOPYRIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉睿健医药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2024097598-A1 | TRIAZINES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-20190177317-A1 | PROCESS FOR THE PREPARATION OF VENETOCLAX | MYLAN LABORATORIES LIMITED (IN) | 2019-06-13 | — | — | US | disclosed |
| US-9174982-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177317-A1 | PROCESS FOR THE PREPARATION OF VENETOCLAX | MCL1, RTCB, VAV1 | USP2 2605/4885GAA 1448/4885ALOX15 2771/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | USP2 2060/4885GAA 1620/4885ALOX15 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.